Quantum BioPharma Ltd. QNTM
Quantum BioPharma Ltd. (Nasdaq: QNTM) is a CNS/neurology/psychiatry drug developer. Its lead program, Lucid-MS (Lucid-21-302), is in Phase 1 for Multiple sclerosis.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| FSD201 (ultramicronized PEA) | Mast cell activation syndrome | small molecule | Phase 2 |
| Lucid-MS | Multiple sclerosis | small molecule | Phase 1 |
| Lucid-PSYCH | Psychiatric | small molecule | Pre-clinical |
Recent results and decisions
- Jun 1, 2026clinical hold FDA placed the Lucid-MS IND on clinical hold (letter received May 28, 2026) pending additional information.
On May 28, 2026, the Company received correspondence from the U.S. Food and Drug Administration ("FDA") indicating that the IND has been placed on clinical hold pending submission of additional information requested by the agency.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.